Roivant Sciences Ltd. (NASDAQ:ROIV) Director Sciences Ltd. Roivant Purchases 16,845,010 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Sciences Ltd. Roivant purchased 16,845,010 shares of the business’s stock in a transaction dated Monday, January 13th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now directly owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Roivant Sciences Price Performance

NASDAQ:ROIV traded up $0.13 during trading hours on Wednesday, reaching $11.07. The company’s stock had a trading volume of 3,878,070 shares, compared to its average volume of 5,040,271. Roivant Sciences Ltd. has a one year low of $9.69 and a one year high of $13.06. The business’s 50-day moving average is $11.83 and its 200-day moving average is $11.59. The company has a market cap of $8.06 billion, a price-to-earnings ratio of 1.96 and a beta of 1.27.

Institutional Trading of Roivant Sciences

Large investors have recently made changes to their positions in the stock. Miracle Mile Advisors LLC bought a new position in shares of Roivant Sciences in the fourth quarter worth about $148,000. Wedmont Private Capital bought a new position in Roivant Sciences in the 4th quarter worth approximately $134,000. ORG Wealth Partners LLC lifted its holdings in shares of Roivant Sciences by 85.7% during the fourth quarter. ORG Wealth Partners LLC now owns 18,240 shares of the company’s stock worth $216,000 after buying an additional 8,417 shares during the last quarter. Nordea Investment Management AB boosted its position in shares of Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock valued at $3,306,000 after acquiring an additional 52,031 shares during the period. Finally, Everence Capital Management Inc. acquired a new stake in Roivant Sciences in the 4th quarter worth $162,000. Institutional investors own 64.76% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.